$357 Million is the total value of Medicxi Ventures Management (Jersey) Ltd's 6 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CNTA | CENTESSA PHARMACEUTICALS PLCsponsored ads | $123,571,942 | +60.8% | 19,963,157 | 0.0% | 34.62% | +5.1% | |
MRUS | MERUS N V | $42,128,000 | +43.1% | 1,600,000 | 0.0% | 11.80% | -6.4% | |
AURA BIOSCIENCES INC | $37,542,666 | +33.1% | 3,039,892 | 0.0% | 10.52% | -13.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Francesco De Rubertis #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-07-19
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
PHATHOM PHARMACEUTICALS INC | 16 | Q3 2023 | 69.8% |
MERUS N V | 16 | Q3 2023 | 25.3% |
VAXCYTE INC | 14 | Q3 2023 | 44.5% |
OBSEVA SA | 12 | Q3 2022 | 5.7% |
CENTESSA PHARMACEUTICALS PLC | 10 | Q3 2023 | 71.3% |
AURA BIOSCIENCES INC | 8 | Q3 2023 | 22.9% |
CHECKMATE PHARMACEUTICALS IN | 8 | Q2 2022 | 12.7% |
NEWAMSTERDAM PHARMA COMPANY | 4 | Q3 2023 | 11.4% |
SYNTHORX INC | 1 | Q4 2019 | 43.1% |
View Medicxi Ventures Management (Jersey) Ltd's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-04-15 |
13F-HR | 2024-02-01 |
3 | 2024-01-26 |
13F-HR | 2023-10-18 |
13F-HR | 2023-07-19 |
13F-HR | 2023-04-27 |
13F-HR | 2023-01-31 |
13F-HR | 2022-10-25 |
13F-HR/A | 2022-08-03 |
13F-HR | 2022-08-03 |
View Medicxi Ventures Management (Jersey) Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.